ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Nominations now open for ‘Company of the Year’ Award 2022
This article features commentary from CEO Steve Cutler about ICON being awarded 2021 Company of the Year.
A blended solution – how midsize pharmaceutical and biotech companies can optimise the delivery of their clinical trials
John Barry, SVP and Chief Strategy Officer of ICON’s Strategic Solutions Division, considers the benefits of a blended model that combines FSP scale and CRO project-based sourcing for mid- size pharmaceutical and biotech companies.
How real world evidence is impacting rare disease drug development
Will Maier, VP of Rare Diseases, shares how a more patient-focused approach to trials is leading to alternatives for randomisation.
Incorporating patient preference vital to study success
Jayne Galinsky, Senior Outcomes Researcher, shares the importance of learning and assessing patient preferences in clinical research.
Patient voice, empathy key to paediatric study design
Jacqui Whiteway, Senior Director of the Centre for Paediatric Clinical Development, discusses the unique challenges involved in designing a study when the patients involved are young children.
The cross-over of statistical thinking and practices: A pandemic catalyst
This article by Dr. Andy Garret, EVP Scientific Operations, focuses on what others could learn from good statistical practices in drug development, and considers areas where drug development could benefit from some fresh thinking and challenge.
Tech advances making decentralised trial growth possible
Dr. Isaac R. Rodriguez-Chavez, Senior Vice President, Scientific and Clinical Affairs at ICON discusses the technology advancements that are making decentralised trial growth possible.
Decentralised clinical trial transformations are ‘here to stay’
Dr. Isaac R. Rodriguez-Chavez, Senior Vice President, Scientific and Clinical Affairs at ICON, discusses the various factors behind the DCT format's rapid rise and likely longevity in the drug development arena.
Improving early phase oncology clinical trial design: A case study
Tim Clark, VP Drug Development Solutions and Alan Phillips, Sr. Director Biostatistics present a case study on the first in human Bayesian Optimal Interval design.
ICON wins ‘Company of the Year’ at the Business & Finance Awards 2022
Steve Culter gives insight into ICON as a company along with his thoughts on winning this award.